Immunohistochemical validation of TLE1, a novel maxrker, for synovial sarcomas

Indian Journal of Medical Research

Volumn 136, Issue 5, 2012, Pages 766-775

  Rekhi, Bharat ^a   Basak, Ranjan ^b   Desai, Sangeeta B ^b   Jambhekar, Nirmala A ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Research and Education in Cancer ACTREC   (India)

Author keywords

Immunohistochemistry of synovial sarcoma; Molecular analysis of synovial sarcomas; Synovial sarcoma; T(X; 18) (SYT SSX); TLE1

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; PROTEIN BCL 2; TRANSDUCIN LIKE ENHANCER OF SPLIT 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SARCOMA, SYNOVIAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872055965     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. th ed. St Louis: Mosby; 2001.
2. Fisher C, Bruijn DRH, Geurts van Kessel A. Synovial Sarcoma. In: Tumors of soft tissue and bone. Pathology and genetics. World Health Organization classification of tumors. Fletcher CDM, Unni K, Mertens F, editors. Lyon: IARC Press; 2002. p. 200-4.
3. Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998; 6: 40-21.
4. Machen SK, Fisher C, Gautam RS, Tubbs RR, Goldblum JR. Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumor. Histopathology 1998; 33: 501-7.
5. Suster S, Fisher C, Moran CA. Expression of BCL-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998; 22: 863-72.
6. Fisher C, Montgomery E, Healy V. Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. Histopathology 2003; 42: 588-93.
7. Dei Tos AP, Wadden C, Calonje E, Sciot R, Pauwels P, Knight, JC, et al. Immunohistochemical demonstration of glycoperotein 30/mic2 (CD99) in synovial sarcoma: a potential cause of dagnostic confusion. Appl Immunohistochem 1995; 3: 168-73.
8. Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous and poorly differentiated synovial sarcoma: Immunohistochemical reassessment of 60 t(X; 18) (SYT-SSX)-positive cases. Am J Surg Pathol 2002; 26: 1434-40.
9. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 2001; 32: 257-63.
10. Saito T, Oda Y, Sakamoto A, Tamiya S, Iwamoto Y, Tsuneyoshi M. Matrix metalloproteinase-2 expression correlates with morphological and immunohistochemical epithelial characteristics in synovial sarcoma. Histopathology 2002; 40: 279-85.
11. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, et al. Identification of novel genes, SYT and SSX, involved in the t(X; 18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502-8.
12. Lasota J, Jasinski M, Debiec-Rychter M, Szadowska A, Limon J, Miettinen M. Detection of the SYT-SSX fusion transcripts in formaldehyde-fixed, paraffin-embedded tissue: a reverse transcription polymerase chain reaction amplification assay useful in the diagnosis of synovial sarcoma. Mod Pathol 1998; 11: 626-33.
13. Guillou L, Coindre J, Gallagher G, Gebhard S, de Saint Aubain Somerhausen N, et al. Detection of the synovial sarcoma translocation t(X; 18) (SYT; SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 2001; 32: 105-12.
14. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001; 20: 5755-62.
15. Ladayni M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multinstitutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-40.
16. Cole P, Ladanyi M, Gerald WL, Cheung NK, Kramer K, LaQuaglia MP, et al. Synovial sarcoma mimicking desmoplastic small round-cell tumor: critical role for molecular diagnosis. Med Pediatr Oncol 1999; 32: 97-101.
17. Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007; 31: 240-6.
18. Stifani S, Blaumueller CM, Redhead NJ, Hill RE, Artavanis-Tsakonas S. Human homologs of a Drosophila enhancer of split gene product define a novel family of nuclear proteins. Nat Genet 1992; 2: 119-27.
19. Allander SV, Ille PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, et al. Expression profiling of synovial sarcoma by cDNA microaarays association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002; 161: 1587-95.
20. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, et al. Molecular characterization of soft tissue tumors: a gene expression study. Lancet 2002; 359: 1301-7.
21. Knösel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X; 18): analysis of 319 cases. Eur J Cancer 2010; 46: 1170-6.
22. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol 2009; 33: 1743-51.
23. Foo WC, Cruise MW, Wick MR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol 2011; 135: 839-44.
24. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 2009; 22: 872-8.
25. Storlazzi CT, Mertens F, Mandhal N, Gisselsson D, Isaksson M, Gustafson P, et al. A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer 2003; 37: 195-200.
26. Lestou VS, O'Connell JX, Robichaud M, Salski C, Mathers J, Maguire J, et al. Cryptic t(X; 18), ins (6; 18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma. Cancer Genet Cytogenet 2002; 138: 153-6.
27. Torres L, Lisboa S, Cerveira N, Lopes JM, Lopes C, Teixeira MR. Cryptic chromosome rearrangement resulting in SYT- SSX2 fusion gene in a monophasic synovial sarcoma. Cancer Genet Cytogenet 2008; 187: 45-9.
28. He R, Patel RM, Alkan S, Hammadeh R, Weiss SW, Goldblum JR, et al. Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. Mod Pathol 2007; 20: 522-8.
29. Matsuyama A, Hisaoka M, Iwasaki M, Iwashita M, Hisanaga S, Hashimoto H. TLE1 expression in malignant mesothelioma. Virchows Arch 2010; 457: 577-83.
30. Inagaki H, Murase T, Otsuka T, Eimoto T. Detection of SYT- SSX fusion transcript in synovial sarcoma using archival cytologic specimens. Am J Clin Pathol 1999; 111: 528-33.